DiaSorin S.p.A. (LON:0GZX)

Market Cap	3.32B
Revenue (ttm)	1.06B +2.7%
Net Income	160.70M -2.5%
EPS	2.98
Shares Out	n/a
PE Ratio	20.64
Forward PE	16.33
Dividend	1.01 (1.38%)
Ex-Dividend Date	May 19, 2025

Volume	98,945
Average Volume	267,145
Open	73.16
Previous Close	73.28
Day's Range	70.66 - 72.40
52-Week Range	58.14 - 107.40
Beta	0.57
RSI	51.24
Earnings Date	Mar 13, 2026

About DiaSorin

DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/sepsis, bone metabolism, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urin...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1968
• Employees: 3,280
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GZX

Financial Performance

In 2024, DiaSorin's revenue was 1.19 billion, an increase of 3.24% compared to the previous year's 1.15 billion. Earnings were 188.11 million, an increase of 17.68%.

Financial numbers in EUR